A Neurofeedback Intervention to Improve Working Memory in Schizophrenia

Sponsor
University of California, San Diego (Other)
Overall Status
Recruiting
CT.gov ID
NCT03260257
Collaborator
National Institutes of Health (NIH) (NIH)
80
1
1
70
1.1

Study Details

Study Description

Brief Summary

Schizophrenia affects 2.4 million Americans and causes significant individual and societal costs. Cognitive deficits including poor working memory arise early in the course of illness, account for poor long-term outcomes and have been difficult to treat with available treatments. The investigators are proposing to develop a novel, computer-based brain training to improve working memory in schizophrenia patients, which, if successful could have significant personal, societal, and economic impact.

Condition or Disease Intervention/Treatment Phase
  • Other: Neurofeedback
N/A

Detailed Description

Schizophrenia (SCZ) is a chronic debilitating mental disorder that affects 2.4 million Americans and leads to considerable individual and societal costs. In patients with SCZ, cognitive deficits (CD) occur early in the course of the illness, are associated with more severe illness, and are the best predictor of functional outcomes. Nonetheless, to date, CD have been difficult to treat using available treatments. Recent studies suggest CD in patients with SCZ may arise from abnormal synchronization of distributed neural networks. Synchronization or synchronous firing of neurons, binds cortical areas into functional networks in a task and state-dependent manner. Thus novel therapies that improve abnormal neural synchrony may improve previously refractory symptoms arising from disordered brain networks.

Neural synchrony or coherence in the gamma band (GBR, 30-45Hz) plays a central role in top-down attention, multisensory processing, perceptual binding and working memory (WM). Patients with SCZ exhibit abnormal GBR, and the magnitude of impairment is associated with the severity of cognitive disorganization. Given these results, improving GBR should improve CD, including WM in SCZ. This hypothesis has been tested and confirmed using repetitive transcranial magnetic stimulation (rTMS). Additionally, EEG-based neurofeedback (NFB) is hypothesized to improve GBR and cognitive function in patients with SCZ. NFB is a low-cost, easily administered and well-tolerated treatment. In healthy controls, Gamma-NFB improves GBR and cognitive function including WM. Thus, the investigators propose testing the feasibility and effectiveness of improving GBR using gamma-NFB in patients with SCZ using the framework of the R61/R33 mechanism.

The first trial (R61) is a proof-of-concept study designed to assess target engagement and dose response curve. Thirty SCZ patients will receive G-NFB training for 12 weeks (2 weekly sessions of 30minute duration) and be assessed for 1) evidence of training, 2) Change in GBR, 3) Change in WM and 4) Change in community functioning. The second trial (R33) aims to confirm target engagement based on training parameters obtained from R61, and to assess whether G-NFB is superior to an active-placebo neurofeedback intervention in improving GBR, WM and community functioning.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Enhancing Gamma Band Response in Schizophrenia to Improve Working
Actual Study Start Date :
Mar 1, 2018
Anticipated Primary Completion Date :
Sep 30, 2023
Anticipated Study Completion Date :
Dec 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Schizophrenia patients

Thirty SCZ patients will receive neurofeedback to enhance gamma band response in an open-label, proof of concept study.

Other: Neurofeedback
Neurofeedback (NFB) will be administered to improve gamma band response. NFBs effects will be measured on gamma coherence and working memory.

Outcome Measures

Primary Outcome Measures

  1. Change in Task related Gamma band response (gamma coherence and power) [This variable will be assessed at t=0, 4 weeks, 8 weeks, 12 weeks and 4 weeks post completion of intervention]

    Gamma-NFBs effects on gamma coherence and gamma power over time will be assessed.

Secondary Outcome Measures

  1. Change in Working memory [This variable will be assessed at t=0, 12 weeks, and 4 weeks post study completion.]

    Gamma-NFBs effects on non-verbal working memory will be assessed over time.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of schizophrenia/schizoaffective disorder
Exclusion Criteria:
  • Active substance use disorders in the last 30 days

  • Medication changes in the last 30 days

  • History of traumatic brain injury

  • seizure disorder

  • pregnancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of California at San Diego La Jolla California United States 92093

Sponsors and Collaborators

  • University of California, San Diego
  • National Institutes of Health (NIH)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fiza Singh, Assistant Clinical Professor, University of California, San Diego
ClinicalTrials.gov Identifier:
NCT03260257
Other Study ID Numbers:
  • 171020
First Posted:
Aug 24, 2017
Last Update Posted:
Mar 29, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Fiza Singh, Assistant Clinical Professor, University of California, San Diego
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 29, 2022